Aurinia Pharmaceuticals Inc.
US ˙ NasdaqGM ˙ CA05156V1022

SecurityAUPH / Aurinia Pharmaceuticals Inc.
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership1,572,983 shares
Latest Disclosed Value $ 23,311,608
D. E. Shaw & Co., Inc. reports 2.66% increase in ownership of AUPH / Aurinia Pharmaceuticals Inc.

On May 15, 2026 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 1,572,983 shares of Aurinia Pharmaceuticals Inc. (US:AUPH) valued at $23,311,608 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,532,273 shares of Aurinia Pharmaceuticals Inc.. This represents a change in shares of 2.66% during the quarter. The current value of the position is $24,648,644 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 1,572,983 40,710 2.66 23,312 -4.62 0.0140
2026-02-17 2025-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 1,532,273 622,351 68.40 24,440 143.08 0.0134
2025-11-14 2025-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 909,922 568,382 166.42 10,055 247.65 0.0057
2025-08-14 2025-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 341,540 77,117 29.16 2,893 36.09 0.0021
2025-05-15 2025-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 264,423 131,090 98.32 2,126 77.53 0.0019
2025-02-14 2024-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 133,333 39,384 41.92 1,197 73.98 0.0009
2024-11-14 2024-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 93,949 8,055 9.38 689 40.41 0.0006
2024-08-14 2024-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 85,894 4,152 5.08 490 19.80 0.0005
2024-05-15 2024-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 81,742 -10,820 -11.69 410 -50.84 0.0004
2024-02-14 2023-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 92,562 -264,584 -74.08 832 -70.02 0.0007
2023-11-14 2023-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 357,146 -256,367 -41.79 2,775 -53.27 0.0029
2023-08-14 2023-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 613,513 108,259 21.43 5,939 7.24 0.0061
2023-05-15 2023-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 505,254 398,970 375.38 5,538 1,106.32 0.0059
2023-02-14 2022-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 106,284 6,447 6.46 459 -38.88 0.0005
2022-11-14 2022-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 99,837 -13,723 -12.08 751 -34.18 0.0009
2022-08-15 2022-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 113,560 34,647 43.91 1,141 16.79 0.0013
2022-05-16 2022-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 78,913 -109,420 -58.10 977 -77.32 0.0009
2022-02-14 2021-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 188,333 -145,536 -43.59 4,307 -41.71 0.0036
2021-11-15 2021-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 333,869 294,258 742.87 7,389 1,340.35 0.0067
2021-08-16 2021-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 39,611 27,776 234.69 513 233.12 0.0004
2021-05-17 2021-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 11,835 -289,198 -96.07 154 -96.30 0.0001
2021-02-16 2020-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 301,033 -38,006 -11.21 4,158 -16.71 0.0037
2020-11-16 2020-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 339,039 222,073 189.86 4,992 162.88 0.0051
2020-08-14 2020-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 116,966 -5,672 -4.62 1,899 6.75 0.0023
2020-05-15 2020-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 122,638 122,638 1,779 0.0028
2020-02-14 2019-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 0 -335,027 -100.00 0 -100.00
2019-11-14 2019-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 335,027 -58,273 -14.82 1,789 -30.87 0.0022
2019-08-14 2019-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 393,300 -154,898 -28.26 2,588 -27.38 0.0032
2019-05-15 2019-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 548,198 159,387 40.99 3,564 34.39 0.0046
2019-02-14 2018-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 388,811 124,940 47.35 2,652 51.37 0.0037
2018-11-14 2018-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 263,871 148,399 128.52 1,752 169.54 0.0021
2018-08-14 2018-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 115,472 -117,161 -50.36 650 -46.15 0.0008
2018-05-15 2018-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 232,633 232,633 1,207 0.0016
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.